Journal article
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective
Abstract
BackgroundRivaroxaban 2.5 mg twice daily with aspirin 100 mg daily was shown to be better than aspirin 100 mg daily for preventing cardiovascular (CV) death, stroke or myocardial infarction in patients with either stable coronary artery disease (CAD) or peripheral artery disease (PAD). The cost-effectiveness of this regimen in this population is essential for decision-makers to know.MethodsUS direct healthcare system costs (in USD) were applied …
Authors
Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH
Journal
American Journal of Cardiovascular Drugs, Vol. 24, No. 1, pp. 117–127
Publisher
Springer Nature
Publication Date
1 2024
DOI
10.1007/s40256-023-00620-6
ISSN
1175-3277